Danielsen Else R, Lund Allan M, Thomsen Carsten
, 9, Blegdamsvej, Section X3023, DK-2100, Copenhagen Ø, Denmark,
JIMD Rep. 2013;11:49-52. doi: 10.1007/8904_2013_221. Epub 2013 Apr 24.
α-Mannosidosis, OMIM #248500, is an autosomal recessive lysosomal storage disease caused by acidic α-mannosidase deficiency. Treatment options include bone marrow transplantation (BMT) and, possibly in the future, enzyme replacement therapy. Brain magnetic resonance spectroscopy (MRS) enables non-invasive monitoring of cerebral treatment effect. Accumulated cerebral mannose-containing oligosaccharides were demonstrated by MRS in a patient who at age 2 years and 11 months received a BMT from a haploidentical non-carrier sibling. The cerebral mannose-containing oligosaccharides had disappeared as early as 9½ months after BMT. MRS furthermore demonstrated the persistent treatment effect at regular intervals up to 5½ years after BMT. MRS is a non-invasive tool that can demonstrate the effect of BMT treatment. Likewise, MRS may be used to demonstrate the cerebral effect of other potential treatments such as enzyme replacement therapy.
α-甘露糖苷贮积症(OMIM #248500)是一种常染色体隐性溶酶体贮积病,由酸性α-甘露糖苷酶缺乏引起。治疗选择包括骨髓移植(BMT),未来可能还包括酶替代疗法。脑磁共振波谱(MRS)能够对脑部治疗效果进行无创监测。在一名2岁11个月大的患者中,MRS证实了脑部存在累积的含甘露糖寡糖,该患者接受了来自单倍体相合的非携带者同胞的BMT。含甘露糖的脑寡糖在BMT后早在9个半月时就已消失。MRS还显示在BMT后长达5年半的时间里,治疗效果持续存在。MRS是一种无创工具,可证明BMT治疗的效果。同样,MRS可用于证明其他潜在治疗方法(如酶替代疗法)对脑部的影响。